# Phase 1/2 sarcoma trials recruiting: 51 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 51 trials in phase 1/2 for sarcoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 sarcoma trials: 51 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/sarcoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 51
- Recruiting or not yet: 51
- Read on: November 19, 2026

## Trials

The 25 newest of 51, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07941362 | 177Lu-ACT319 in FAP Expressing Solid Tumors | Actithera INC. | Phase 1/2 | Not yet recruiting | FAP-expressing Solid Tumors, Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Carcinoma (BTC) | 182 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941362) |
| September 21, 2026 | NCT07830667 | A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are... | Children's Oncology Group | Phase 1/2 | Not yet recruiting | Recurrent Childhood Ewing Sarcoma, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Rhabdomyosarcoma... | 79 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830667) |
| September 10, 2026 | NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | Advenchen Pharmaceuticals, LLC. | Phase 1/2 | Not yet recruiting | Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811297) |
| September 10, 2026 | NCT07811232 | A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers | Advenchen Pharmaceuticals, LLC. | Phase 1/2 | Not yet recruiting | Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811232) |
| September 3, 2026 | NCT07801222 | A Study to Assess Safety and Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma or Soft... | SOTIO Biotech a.s. | Phase 1/2 | Not yet recruiting | Osteosarcoma Metastatic, Soft Tissue Sarcoma (STS), Osteosarcoma, Advanced | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801222) |
| July 29, 2026 | NCT07734116 | A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma. | Ono Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Pediatric Malignant Solid Tumor and Epithelioid Sarcoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07734116) |
| July 24, 2026 | NCT07725380 | Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma | H. Lee Moffitt Cancer Center and Research Institute | Phase 1/2 | Recruiting | Sarcoma, Osteosarcoma | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07725380) |
| May 22, 2026 | NCT07602777 | A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) | GlaxoSmithKline | Phase 1/2 | Recruiting | Sarcoma | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07602777) |
| March 10, 2026 | NCT07460986 | A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma. | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Soft Tissue Sarcoma (STS) | 278 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07460986) |
| February 13, 2026 | NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic), Lung Cancer (Diagnosis), Colorectal Cancer... | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410676) |
| September 24, 2025 | NCT07189871 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors | Radiopharm Theranostics, Ltd | Phase 1/2 | Recruiting | Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer... | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07189871) |
| July 15, 2025 | NCT07066982 | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas | Essen Biotech | Phase 1/2 | Recruiting | Sarcoma, Sarcoma, Kaposi, Sarcoma, Ewing, Sarcoma,Soft Tissue, Sarcoma of Bone and Connective Tissue, Sarcoma... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07066982) |
| July 14, 2025 | NCT07064018 | Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies | University of California, Irvine | Phase 1/2 | Recruiting | Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Ovarian Cancer, KRAS... | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07064018) |
| May 16, 2025 | NCT06975293 | STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected... | STORM Therapeutics LTD | Phase 1/2 | Recruiting | Solid Tumor, Sarcoma, Leiomyosarcoma, Dedifferentiated Liposarcoma | 107 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06975293) |
| April 24, 2025 | NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | Tanabe Pharma America, Inc. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06943521) |
| January 29, 2025 | NCT06797999 | First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06797999) |
| November 29, 2024 | NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | Perspective Therapeutics | Phase 1/2 | Recruiting | Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck... | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06710756) |
| November 29, 2024 | NCT06709495 | Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young... | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor, Refractory Sarcoma, Osteosarcoma, Rhabdomyosarcoma | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06709495) |
| October 3, 2024 | NCT06625190 | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | University of Florida | Phase 1/2 | Recruiting | Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors, Clear Cell Sarcoma, Alveolar Soft... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06625190) |
| September 23, 2024 | NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent... | Fundación de investigación HM | Phase 1/2 | Recruiting | Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas, Meningioma, Paraganglioma... | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06607692) |
| August 7, 2024 | NCT06541262 | Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | Milton S. Hershey Medical Center | Phase 1/2 | Recruiting | Neuroblastoma, Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Liposarcoma | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06541262) |
| July 12, 2024 | NCT06498648 | Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma, Metastatic... | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06498648) |
| June 18, 2024 | NCT06465199 | Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | Milton S. Hershey Medical Center | Phase 1/2 | Recruiting | Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes, Ewing Sarcoma, Diffuse Intrinsic Pontine... | 265 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06465199) |
| May 1, 2024 | NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors... | Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06395103) |
| March 7, 2024 | NCT06298916 | 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer | Lantheus Medical Imaging | Phase 1/2 | Recruiting | Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Sarcoma | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06298916) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 3 |
| Milton S. Hershey Medical Center | 2 |
| Essen Biotech | 2 |
| Children's Oncology Group | 2 |
| Advenchen Pharmaceuticals, LLC. | 2 |
| Turning Point Therapeutics, Inc. | 2 |
| University of Florida | 2 |
| St. Jude Children's Research Hospital | 2 |
| Shenzhen Geno-Immune Medical Institute | 2 |
| Grupo Espanol de Investigacion en Sarcomas | 1 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 1 |
| SOTIO Biotech a.s. | 1 |
| Perspective Therapeutics | 1 |
| STORM Therapeutics LTD | 1 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 1 |
| Cancer Research UK | 1 |
| Roswell Park Cancer Institute | 1 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| Second Affiliated Hospital of Guangzhou Medical University | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| Tango Therapeutics, Inc. | 1 |
| GI Innovation, Inc. | 1 |
| [Ono Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/ono-pharmaceutical-co-ltd) | 1 |
| USWM CT, LLC | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 36 |
| France | 7 |
| Spain | 7 |
| Canada | 7 |
| China | 7 |
| United Kingdom | 6 |
| Italy | 4 |
| Australia | 4 |
| Germany | 4 |
| South Korea | 4 |
| Japan | 4 |
| Belgium | 3 |
| Denmark | 3 |
| Israel | 3 |
| Taiwan | 3 |
| Hungary | 2 |
| Netherlands | 2 |
| Singapore | 2 |
| Brazil | 1 |
| Chile | 1 |
| Colombia | 1 |
| Czechia | 1 |
| Greece | 1 |
| Slovakia | 1 |
| Sweden | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Dental hygiene clinics in the United States](https://specstream.ai/data/businesses/dental-hygiene-clinics/united-states)
- [Employment law firms in the United States](https://specstream.ai/data/businesses/employment-law-firms/united-states)
- [Flour mills in the United States](https://specstream.ai/data/businesses/flour-mills/united-states)
- [Health insurance offices in the United States](https://specstream.ai/data/businesses/health-insurance-offices/united-states)
- [Insurance agencies in the United States](https://specstream.ai/data/businesses/insurance-agencies/united-states)
- [Live and raw food restaurants in the United States](https://specstream.ai/data/businesses/live-and-raw-food-restaurants/united-states)
